Since our Association was founded in 2009, we have hosted dozens of programs to bring together scientists across the many silos of biomedical research. In 2014 we held our first Annual Meeting at the beautiful Center for Dermal Research at Rutgers. We heard a great talk by Gabor Fari of Microsoft on the way that Cloud Computing is changing science (the recording is in our archive- click here).

This year, we're celebrating our growing international community by making the entire meeting virtual. While it certainly can't replace a chance to meet someone new at the coffee urn, we hope you'll join us for the official launch of our 2015 programming, and acknowledgement of the many speakers, sponsors, committee members, volunteers, and board members who have made our deepening relationships possible.

In addition to discussing his own work, he'll share the strategies that are driving the two publications for which he is the Co-Editor in Chief: The Journal of Circulating Biomarkers and Nanobiomedicine.

Recently appointed to our Scientific Advisory Board, Dr. Winston Patrick Kuo is one of our Outstanding Contributors. Beginning in early 2014, we worked together to develop the very successful web based Short Course in Extracellular Vesicles (Exosomes and Microvesicles) and a publication in the open-access journal, Journal of Circulating Biomarkers (InTech Publishers). He worked with all of the speakers to develop a strong curriculum that has stimulated great discussion. He is currently working with Dr. Howard Young to develop the upcoming Short Course in the Microbiome (April 2015) and more to come.

 

About Our Keynote

Winston Kuo DMSc is currently the COO of IES Diagnostics, which is developing the Rapid Ebola Pre-Symptom Screening Test.

Recipients Opening Their Award

 Winston Kuo DMSc

Winston Kuo DMSc

 Howard Young

Howard Young

 Danielle Macario

Danielle Macario

 Frances Ligler

Frances Ligler

 Rodolphe Barrangou

Rodolphe Barrangou

He is the founder of Harvard Medical School’s Laboratory for Innovative Translational Technologies, which was an integral part of the Clinical and Translational Science Award program, Dr. Kuo has founded and supported many programs that spur biomedical research.

He initiated and participated with the FDA in a large-scale comprehensive study evaluating the clinical utility of gene expression technologies, published in Nature Biotechnology (July 2006). He sits on the NIH/SBIR grant review study section and is a peer reviewer for the Qatar National Research Fund.

Dr. Kuo's clinical and translational initiatives have expanded globally in developing countries such as Brazil, China, Mongolia, Nigeria, Saudi Arabia and South Africa, focusing upon accelerating understanding of mechanisms that affect human disease; catalyzing the identification and development of useful biomarkers; and speeding the development of therapeutics in patients. Dr. Kuo has also instructed in the Innovation for Economic Development program at the Harvard Kennedy School of Government.

Dr. Kuo is a founder and Trustee of the Otto Heinrich Warburg Cancer Research Foundation. He sits on the editorial boards of multiple peer reviewed journals, has consulted with the NIH on interdisciplinary outreach, and sits on a number business and nonprofit Scientific Advisory Boards. He received is Doctor of Medical Sciences (DMSc), Oral and Computational Biology from Harvard Medical School.